Two insiders, including a director with no previous sales pattern, are liquidating significant positions at ~$80/share. Monitor for an upcoming news event or data readout that could explain this cluster; if an 8-K or presentation follows within 14 days, the cluster likely signals informed selling ahead of negative catalysts. The PROPORTIONALITY IS MODEST but the DETERMINATION (12 director transactions in 3 days) creates a caution flag for a $3.1B biotech at 95% analyst buy consensus.
IRON drugs
IRON drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 4 $79.23entry
- T+1 · 2mo ago −3.02%α −2.47% · $76.84
- T+5 · 2mo ago −13.01%α −11.80% · $68.92
- T+20 · 6w ago −20.07%α −20.67% · $63.33
- T+50 · todayOpen
- T+60 · in 14d Pending
Price Chart
How similar events traded
Executive Summary
Director Kevin Bitterman sold ~$4.4M of IRON stock in a concentrated 7-day cluster, while COO Jonathan Yu sold $731K. The cluster is dominated by open-market sales (no 10b5-1 pattern evident) across two insiders, with Bitterman's sales alone representing ~0.14% of the company's $3.1B market cap. While the total dollar value is modest relative to market cap, the concentrated selling by a director warrants attention given the stock's 95% analyst buy rating and recent positive clinical momentum.
Key Financial Metrics
Key Facts
- Director Kevin Bitterman sold 54,446 shares total over 12 transactions in 3 days, netting ~$4.37M
- COO Jonathan Yu sold 8,800 shares at $83.12 on Aug 25, netting ~$731K
- Combined insider selling of ~$5.1M represents ~0.16% of IRON's $3.1B market cap
- All transactions were open-market sales; no option exercises or tax-withholding transactions
- Director Bitterman sold in 12 separate transactions across Sept 1-3, suggesting determined liquidation rather than routine plan
- No insider buying occurred in this cluster or the prior 30-day period (10 sells totaling $4.4M)
Financial Impact
~$5.1M insider selling (0.16% of market cap) concentrated in 7-day window; director alone sold ~$4.37M
Risk Factors
- Potential negative catalyst (clinical trial update, regulatory setback, or partnership failure) within weeks
- Insider sales may signal management's private view that stock is fully valued at $80 despite bullish analyst consensus
- Concentrated director selling pattern could accelerate if fundamental thesis deteriorates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IRON-1788472049519 |
Track record
43 reports on IRON
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +17.13% at T+60 after the Jun 9, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers